Prime Highlight:
- Omada Health will begin prescribing GLP-1s and other obesity medications as part of its expanded virtual weight management program.
- The program combines lifestyle, behavioral support, and medical supervision to help patients manage medications effectively.
Key Facts:
- Omada’s membership has grown to over 800,000 users, reflecting rising demand for GLP-1 treatments.
- Licensed providers will guide patients on nutrition, exercise, dosage adjustments, and side effect management during the treatment journey.
Background
Virtual care company Omada Health announced on Thursday that it will start prescribing GLP-1s and other obesity drugs as part of its expanded weight management program. The initiative comes as the company’s membership has grown to more than 800,000 users.
The decision follows the rising demand for GLP-1 medications, a category of drugs widely used to treat obesity, diabetes, and other chronic conditions. Analysts estimate the global market for GLP-1s could reach $100 billion by the end of the decade.
According to Omada co-founder and CEO Sean Duffy, the move reflects the company’s belief that access to GLP-1s will continue to grow and evolve beyond injections to include pills and other next-generation treatments.
Omada’s program combines lifestyle and behavioral support with medical supervision. Licensed providers trained in obesity care will guide patients on nutrition, exercise, and medication management. These experts will help patients handle dosage adjustments, manage side effects, and stay on their treatment plans effectively.
Duffy emphasized that the goal is to provide comprehensive support throughout the medication journey, especially since GLP-1s can be complex to use and often cause gastrointestinal side effects.
Omada, which partners with health plans and employers nationwide, said the new service is an add-on offering to help companies improve employee health outcomes while managing healthcare costs.
Founded in 2011, Omada Health provides virtual care programs for chronic conditions including prediabetes, diabetes, and hypertension, operating as a between-visit care model that complements traditional healthcare services.
